Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that C. Evan Ballantyne has joined the Company as Chief Financial Officer. In this position, Mr. Ballantyne will be responsible for all aspects of the Company's financial, accounting and investor relations functions.
From 2006 until its acquisition in April 2011, Mr. Ballantyne served as Executive Vice President and Chief Financial Officer of Clinical Data, Inc., a publicly-traded biopharmaceutical company which ...
read more